PMID- 26306066
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150826
LR  - 20201001
IS  - 0971-4502 (Print)
IS  - 0974-0449 (Electronic)
IS  - 0971-4502 (Linking)
VI  - 31
IP  - 4
DP  - 2015 Dec
TI  - Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Treatment for 
      Relapsed or Refractory Lymphoma.
PG  - 426-33
LID - 10.1007/s12288-014-0497-7 [doi]
AB  - To analyze the efficacy and safety of allogeneic hematopoietic stem cell 
      transplantation (Allo-HSCT) in patients with relapsed or refractory lymphoma, the 
      therapeutic efficacy, safety, and survival of 23 patients were evaluated. There 
      were 18 (78.3 %) patients with relapsed lymphoma and 5 (21.7 %) patients with 
      refractory lymphoma. Patients were grafted from human leukocyte antigen 
      (HLA)-matched (10) or mismatched (7) related donors, or matched unrelated donors 
      (6). The responses after Allo-HSCT included 13 (56.5 %) cases of complete 
      remission, 5 (21.7 %) cases of partial remission, and 5 (21.7 %) cases of 
      progressive disease. Overall, 16 of 23 patients were alive at a median follow up 
      of 1,035 days (range 60-2,613), five patients died because of non-relapsed 
      mortality, and two patients died of progressive disease. Progression-free 
      survival rates were 64.6 and 48.4 % at 12 and 24 months, respectively, and 
      overall survival rates were 68.6 and 59.5 % at 12 and 24 months, respectively. 
      Allo-HSCT may be a salvage treatment for relapsed or refractory lymphoma. 
      Myeloablative conditioning regimens may be effective and safe.
FAU - Wang, Jing-Shi
AU  - Wang JS
AD  - Department of Hematology, Beijing Friendship Hospital, Capital Medical 
      University, No. 95 Yong'an Road, Xicheng District, Beijing, 100050 People's 
      Republic of China.
FAU - Wang, Zhao
AU  - Wang Z
AD  - Department of Hematology, Beijing Friendship Hospital, Capital Medical 
      University, No. 95 Yong'an Road, Xicheng District, Beijing, 100050 People's 
      Republic of China.
FAU - Wang, Yi-Ni
AU  - Wang YN
AD  - Department of Hematology, Beijing Friendship Hospital, Capital Medical 
      University, No. 95 Yong'an Road, Xicheng District, Beijing, 100050 People's 
      Republic of China.
FAU - Wu, Lin
AU  - Wu L
AD  - Department of Hematology, Beijing Friendship Hospital, Capital Medical 
      University, No. 95 Yong'an Road, Xicheng District, Beijing, 100050 People's 
      Republic of China.
FAU - Fu, Li
AU  - Fu L
AD  - Department of Hematology, Beijing Friendship Hospital, Capital Medical 
      University, No. 95 Yong'an Road, Xicheng District, Beijing, 100050 People's 
      Republic of China.
FAU - Wei, Na
AU  - Wei N
AD  - Department of Hematology, Beijing Friendship Hospital, Capital Medical 
      University, No. 95 Yong'an Road, Xicheng District, Beijing, 100050 People's 
      Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20150109
PL  - India
TA  - Indian J Hematol Blood Transfus
JT  - Indian journal of hematology & blood transfusion : an official journal of Indian 
      Society of Hematology and Blood Transfusion
JID - 9425818
PMC - PMC4542769
OTO - NOTNLM
OT  - Allogeneic hematopoietic stem cell transplantation
OT  - Lymphoma
OT  - Refractory
OT  - Relapse
EDAT- 2015/08/26 06:00
MHDA- 2015/08/26 06:01
PMCR- 2016/12/01
CRDT- 2015/08/26 06:00
PHST- 2014/10/12 00:00 [received]
PHST- 2014/12/30 00:00 [accepted]
PHST- 2015/08/26 06:00 [entrez]
PHST- 2015/08/26 06:00 [pubmed]
PHST- 2015/08/26 06:01 [medline]
PHST- 2016/12/01 00:00 [pmc-release]
AID - 497 [pii]
AID - 10.1007/s12288-014-0497-7 [doi]
PST - ppublish
SO  - Indian J Hematol Blood Transfus. 2015 Dec;31(4):426-33. doi: 
      10.1007/s12288-014-0497-7. Epub 2015 Jan 9.